AIRLINK 74.39 Increased By ▲ 0.14 (0.19%)
BOP 5.04 Decreased By ▼ -0.01 (-0.2%)
CNERGY 4.55 Increased By ▲ 0.13 (2.94%)
DFML 37.38 Increased By ▲ 1.54 (4.3%)
DGKC 90.80 Increased By ▲ 2.80 (3.18%)
FCCL 22.51 Increased By ▲ 0.31 (1.4%)
FFBL 32.75 Increased By ▲ 0.03 (0.09%)
FFL 9.74 Decreased By ▼ -0.05 (-0.51%)
GGL 10.90 Increased By ▲ 0.10 (0.93%)
HBL 115.80 Decreased By ▼ -0.10 (-0.09%)
HUBC 136.30 Increased By ▲ 0.46 (0.34%)
HUMNL 10.13 Increased By ▲ 0.29 (2.95%)
KEL 4.60 Decreased By ▼ -0.01 (-0.22%)
KOSM 4.98 Increased By ▲ 0.32 (6.87%)
MLCF 40.25 Increased By ▲ 0.37 (0.93%)
OGDC 138.15 Increased By ▲ 0.25 (0.18%)
PAEL 27.39 Increased By ▲ 0.96 (3.63%)
PIAA 24.45 Decreased By ▼ -1.83 (-6.96%)
PIBTL 6.71 Decreased By ▼ -0.05 (-0.74%)
PPL 123.40 Increased By ▲ 0.50 (0.41%)
PRL 27.24 Increased By ▲ 0.55 (2.06%)
PTC 14.08 Increased By ▲ 0.08 (0.57%)
SEARL 59.40 Increased By ▲ 0.70 (1.19%)
SNGP 69.90 Decreased By ▼ -0.50 (-0.71%)
SSGC 10.38 Increased By ▲ 0.02 (0.19%)
TELE 8.65 Increased By ▲ 0.09 (1.05%)
TPLP 11.28 Decreased By ▼ -0.10 (-0.88%)
TRG 64.55 Increased By ▲ 0.32 (0.5%)
UNITY 26.70 Increased By ▲ 0.65 (2.5%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 7,864 Increased By 25.8 (0.33%)
BR30 25,594 Increased By 134 (0.53%)
KSE100 75,312 Increased By 381 (0.51%)
KSE30 24,200 Increased By 53.9 (0.22%)

imagePARIS: Cancer cost the then 27 countries of the European Union 126 billion euros ($170.1 billion) in 2009, according to a study published on Monday.

The bill mainly comprised 51 billion euros in costs for health-scare systems, including drugs; 23 billion euros in unpaid care provided by friends and relatives of people with cancer; and 52 billion euros in lost productivity due to premature deaths and illness.

Britain, France, Germany and Italy accounted for most than two-thirds of the cost.

Four types of cancer -- breast, colorectal, lung and prostate -- contributed to around half of all new cancer diagnoses and deaths.

Lung cancer had the highest overall cost, of 18.8 billion euros, and was also responsible for the biggest loss of productivity.

The analysis should be useful for policymakers weighing decisions on where to allocate research funds, drugs and human resources, said researcher Ramon Luengo-Fernandez of the University of Oxford.

The study appears in The Lancet Oncology.

Comments

Comments are closed.